Privacy Policy

Circassia is committed to ensuring that your privacy is protected. This privacy policy explains how Circassia Pharmaceuticals Inc. (“Circassia”) uses your personal information when you interact with us online through the Duaklir® Pressair® website (“the Website”) and Circassia’s practices for collecting, using, processing, maintaining, protecting, and disclosing that information.

Please read this Policy carefully to understand the Company’s policies and practices regarding your information and how we treat it. By accessing or using this Website, you consent to the terms of this Policy as well as the Terms of Use. If you submit information to this Website, you consent to the collection and use of information as set forth in this Policy. If you do not agree with the Company’s policies and practices, your choice is to not use the Website.

Information We Collect

You may provide personal information directly through our website. Other information is collected automatically. Further information on the personal information we collect is below:

Contact Us. When you choose to contact us through the Website form, we require you to provide your name and email address. You may also choose to provide us with your phone number. We ask for this information in order to respond to your inquiries.

Automatically Collected Information. The Website uses cookies to allow you to automatically store your preferences and to improve the website’s functionality. You can alter the configuration of your browser to refuse to accept cookies, but it is possible that doing so may cause limited functionality of the Website.

Google Analytics. The Website uses Google Analytics to obtain aggregated information about traffic and usage. Google Analytics uses cookies to capture information such as the URL of the page you are viewing, your browser information, and your geographic region. Google Analytics is not affiliated with Circassia and Circassia does not have control over the information that may be collected, used, and shared by Google Analytics. We encourage you to visit Google Analytics’ website to understand its privacy practices.

Use of Personal Information

Except as otherwise required by law, the personal information collected on the Website will be used solely to operate the Website and to provide the service(s) and/or product(s) or carry out the transaction(s) you have requested or authorized. In support of these purposes, Circassia may use personal information to provide you with more effective customer service, send promotional or advertising materials to you (see opt-out provisions below), to improve the Website and any related Circassia products or services, and to make the Website easier to use by eliminating the need for your repeated entry of the same information. In order to offer you a more consistent experience in your interactions with the Circassia, information collected by the Website may be combined with information collected in connection with other Company products and services.

Circassia may occasionally hire other companies to provide limited services on our behalf, such as website hosting, website design or technical support, mailing/shipping, answering customer questions about products and services, and sending information about our products, special offers, and other services. We will only provide those companies the personal information they need to deliver the service. They are required to maintain the confidentiality of the information and are prohibited from using that information for any other purpose.

Circassia may disclose personal information if required to do so by law or in the good faith belief that such action is necessary to (a) conform to the edicts of the law or comply with legal process served on Circassia or the Website; or (b) protect and defend the rights or property of Circassia and the Website. Circassia may also disclose personal information about you if we determine that disclosure is reasonably necessary to enforce our Terms and Conditions, or protect other users of the Website.

Choice/Opt-Out

The Website provides you with the opportunity to choose to receive updates about Circassia and any information we may want you to know about. You may be added to Circassia’s mailing lists and signed up for certain notifications from Circassia when you submit your contact information through the Website. If you would like to be removed from this list and/or opt out of these notifications, please unsubscribe using the instructions in the email or call or write us at the physical address or email address listed below. Please allow five (5) business days for processing of your opt-out request.

If you need to correct or update your contact information, or you no longer desire our services, you can do so by contacting us using the contact information set forth below.

Control of Personal Information

Except as otherwise described in this Privacy Policy, your personal information will not be shared outside of Circassia without your permission.

For persons over the age of 13, providing information about yourself through the Website is free and completely voluntary. No information should be submitted to or posted to the Website by any person under the age of 13 years. Circassia does not knowingly collect information from children under 13. If you are under 13 years old, you may not attempt to provide your information through the Website. If Circassia determines that contact information has submitted by a person under age 13, such information will be removed. If you are between the ages of 13 and 17, you may use the Website only with your parent or guardian’s consent; Circassia reserves the right to request verification of such parent or guardian’s consent. Personal information of persons between ages 13 and 17 will be collected as described in this Privacy Policy. By submitting your contact information through the Website, you represent that you are age 13 or over.

Security

Circassia provides commercially reasonable physical, electronic, and procedural safeguards to protect information it processes through the Website. Please be aware that no security system is foolproof. As a result, we cannot guarantee the security of any information transmitted to us and cannot be responsible for the theft, destruction, misuse, unauthorized access, alteration, or inadvertent disclosure of your personal information.

Circassia stores your personal information for as long as needed: (i) to conduct business with you; (ii) as needed for the purposes outlined in this Privacy Policy or at the time of collection; or (iii) as necessary to comply with legal obligations, resolve disputes, and enforce any agreements.

Third-Party Websites

The Website may contain links to third-party websites; however, please be aware that Circassia is not responsible for, and cannot control, the privacy practices of these other websites. We encourage you to read the privacy policies for these other websites prior to using them, as their privacy practices may differ from ours.

Changes to This Privacy Policy

We reserve the right to update this Privacy Policy from time to time and without notice to you. All such updates shall be effective immediately unless otherwise stated. We encourage you to periodically review this Privacy Policy to stay informed about how we are helping to protect the personal information we collect. Your continued use of the Website constitutes your agreement to this Privacy Policy, as amended from time to time.

Limitations of Privacy Policy

This Privacy Policy explains only data collection and use practices related to Circassia’s Website; it does not apply to other products or services of Circassia. Please be aware that this Privacy Policy and any choices you make on the Website will not necessarily apply to personal information you may have provided to Circassia in the context of other, separately provided, products or services.

Contact Circassia

If you have questions about how Circassia uses your personal information, please contact us at privacy@circassia.com or by regular mail at:

Circassia Pharmaceuticals Inc.
5151 McCrimmon Parkway
Suite 260
Morrisville, NC 27560
Attn: Legal Department

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate,
  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.